IMNM

Immunome, Inc.

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Immunome, Inc. (IMNM) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C- for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
D
Factor Score 1.3 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -7.5
EV / EBITDA -6.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -27.8%
Price Return 12M 16.0%
Catalyst Signal 0.00
Market Cap $2.3B
TTM Revenue $0.0
Price / Sales N/A
ROE -78.7%

Historical Factor Score Progression

Held C- for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) D+ (1.7) D (1.3) C- (2.1) C+ (2.6) C- (2.0)
2026-11-05 C+ (2.5) D (1.5) D (1.3) C (2.2) C+ (2.7) C- (2.0)
2026-10-29 C+ (2.5) D (1.5) D (1.3) C+ (2.5) C+ (2.7) C- (2.1)
2026-10-22 C+ (2.5) D (1.4) D (1.3) C+ (2.8) C+ (2.6) C- (2.1)
2026-10-15 C+ (2.5) D (1.5) D (1.3) C+ (2.7) C+ (2.6) C- (2.1)
Page 1 of 6